Product Description
Neurocrine is developing nbi-74788, an Oral CRFR Antagonist for Congenital Adrenal Hyperplasia. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04045145)
Mechanisms of Action: CRFR Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Neurocrine
Company Location: Western America
Company CEO: Kevin C. Gorman
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Austria, Belgium, Bulgaria, Canada, Czech Republic, France, Germany, Greece, Israel, Italy, Netherlands, Poland, Portugal, Serbia, Spain, Sweden, United Kingdom, United States
Active Clinical Trial Count: 6
Recent & Upcoming Milestones
- Clinical Outcomes Reported - Neurocrine presented P3 Adrenal Hyperplasia, Congenital results on 2025-07-14 for Crinecerfont
- Clinical Outcomes Reported - Neurocrine presented P3 Adrenal Hyperplasia, Congenital results on 2025-05-18 for Crinecerfont
- Clinical Outcomes Reported - Neurocrine presented P3 Adrenal Hyperplasia, Congenital results on 2025-05-08 for Crinecerfont
Highest Development Phases
Phase 3: Adrenal Hyperplasia, Congenital|Adrenocortical Hyperfunction|Adrenogenital Syndrome
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07187375 |
NBI-74788-CAH2011 | P2 |
Recruiting |
Adrenal Hyperplasia, Congenital |
2029-09-06 |
12% |
2025-11-04 |
Primary Endpoints|Start Date|Treatments|Trial Status |
NCT04490915 |
CAHtalyst | P3 |
Active, not recruiting |
Adrenogenital Syndrome|Adrenocortical Hyperfunction|Adrenal Hyperplasia, Congenital |
2023-07-19 |
16% |
2024-05-08 |
Primary Endpoints|Start Date|Treatments |
2024-514127-42-00 |
NBI-74788-CAH2011 | P2 |
Not yet recruiting |
Adrenal Hyperplasia, Congenital |
2029-12-09 |
12% |
||
2023-509170-33-00 |
NBI-74788-CAH2006 | P3 |
Recruiting |
Adrenal Hyperplasia, Congenital |
2027-10-31 |
2025-05-02 |
Treatments |
|
2023-509171-16-00 |
NBI-74788-CAH3003 | P3 |
Recruiting |
Adrenal Hyperplasia, Congenital |
2027-08-31 |
2025-05-02 |
Treatments |
|
NCT04806451 |
CAHtalyst Pediatric Study | P3 |
Active, not recruiting |
Adrenal Hyperplasia, Congenital|Adrenocortical Hyperfunction|Adrenogenital Syndrome |
2023-03-10 |
16% |
2024-05-08 |
Primary Endpoints|Start Date |